For Doctors in a Hurry
- Researchers investigated whether a specific metabolomic signature reflecting systemic inflammation could predict ischemic stroke risk in women.
- This nested case-control study analyzed 1,699 women to derive the signature, then validated it in 454 stroke cases and 454 controls.
- Women in the highest quartile of the inflammatory signature had a 1.76 odds ratio (95% CI 1.02-3.03) for ischemic stroke.
- The researchers concluded that this 102-metabolite profile, primarily involving lysophosphatidylcholine species, independently associates with increased risk for ischemic stroke and coronary disease.
- These findings suggest that inflammatory metabolites may eventually serve as biomarkers to improve risk stratification for atherosclerotic cardiovascular diseases in women.
Ischemic stroke accounts for the vast majority of cerebrovascular events and is a leading cause of long-term disability, with women facing a higher lifetime risk and worse functional outcomes than men [1, 2]. While traditional risk factors are well-defined, systemic inflammation is increasingly recognized as a key contributor to atherosclerotic disease [3]. However, standard inflammatory biomarkers like C-reactive protein often lack the specificity to capture the complex metabolic dysregulation that precedes a clinical event [4]. Advances in metabolomics, the large-scale study of small molecule metabolites, now permit a more granular view of the pathways linking chronic inflammation to vascular occlusion [5]. A new study offers insight into how a specific metabolic profile may help identify women at elevated risk for ischemic stroke, independent of conventional risk factors.
To move beyond general markers of inflammation, researchers sought to develop a more precise tool: an inflammatory metabolomic signature index (i-MSI). The investigation began with a derivation cohort of 1,699 women (mean age 58 years, 94% White) from the Nurses' Health Study. Using data on established inflammatory biomarkers, including high-sensitive C-reactive protein, interleukin 6, tumor necrosis factor receptor 2, and adiponectin, the team applied a statistical machine-learning method known as elastic net regression. This technique sifts through a large volume of data to select the most predictive variables, allowing the researchers to isolate the specific metabolites most strongly associated with a pro-inflammatory state.
This analysis yielded a signature composed of 102 distinct metabolites. The most significant contributors to this inflammatory index were lysophosphatidylcholine species. This finding is clinically relevant because these lipid molecules are known to be directly involved in atherogenesis, where they promote endothelial activation, vascular inflammation, and plaque instability. The i-MSI therefore provides not just a correlational risk score but a potential window into the specific biological mechanisms driving vascular damage.
Clinical Correlation with Incident Ischemic Stroke
To evaluate the clinical utility of the i-MSI, the researchers tested its association with future ischemic stroke in an independent nested case-control study, also drawn from the prospective Nurses' Health Study cohort. This validation group included 454 women who developed ischemic stroke and 454 matched controls, with a mean age of 66 years. The analysis revealed a strong, dose-dependent relationship between the metabolic signature and cerebrovascular risk. After adjusting for multiple variables, women in the highest i-MSI quartile had an odds ratio (OR) of 1.76 (95% CI 1.02-3.03) for ischemic stroke compared to women in the lowest quartile.
When analyzed as a continuous variable, the index's predictive capacity was further confirmed. Each 1-standard deviation increase in the i-MSI was associated with an OR of 1.35 (95% CI 1.09-1.67) for ischemic stroke. Critically for clinical practice, this association was independent of traditional cardiovascular disease risk factors such as hypertension, smoking, and body mass index. These findings suggest the i-MSI captures a distinct biological pathway of vascular risk that is not fully accounted for by current clinical risk calculators, potentially identifying a subset of patients who may benefit from more targeted preventive strategies.
Broader Implications for Atherosclerotic Disease
To assess whether this inflammatory metabolic signature was specific to cerebrovascular disease or reflected a more generalized state of atherosclerosis, the researchers tested its predictive value for coronary heart disease (CHD). This was conducted in an entirely separate cohort from the Women's Health Initiative (WHI), which included 793 women with incident CHD and 795 controls (mean age 67 years). The results demonstrated a consistent pattern of risk across different vascular beds.
In the WHI cohort, each standard deviation increase in the i-MSI was associated with an OR of 1.20 (95% CI 1.05-1.37) for CHD. This consistent finding suggests that the 102-metabolite signature, driven heavily by lysophosphatidylcholines, reflects a systemic vulnerability to atherosclerosis rather than a risk factor confined to the cerebral circulation. For clinicians, this implies that such a metabolic signature could one day serve as a more comprehensive biomarker for atherosclerotic cardiovascular diseases. The authors recommend that future studies should aim to replicate these findings in more diverse populations and evaluate whether these metabolites can be used to improve risk stratification in clinical practice.
References
1. Feigin VL, Stark B, Johnson CO, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021. doi:10.1016/s1474-4422(21)00252-0
2. Dylla L, Higgins H, Piper C, Poisson S, Herson P, Monte A. Sex as a biological variable in determining the metabolic changes influencing acute ischemic stroke outcomes—Where is the data: A systematic review. Frontiers in Neurology. 2022. doi:10.3389/fneur.2022.1026431
3. Anwar L, Ahmad E, Imtiaz M, Ahmad B, Ali MA, Mahnoor. Biomarkers for Early Detection of Stroke: A Systematic Review.. Cureus. 2024. doi:10.7759/cureus.70624
4. Qiu S, Cai Y, Yao H, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01399-3
5. Ke C, Pan C, Zhang Y, Zhu X, Zhang Y. Metabolomics facilitates the discovery of metabolic biomarkers and pathways for ischemic stroke: a systematic review.. Metabolomics : Official journal of the Metabolomic Society. 2019. doi:10.1007/s11306-019-1615-1
